Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma

  • STATUS
    Recruiting
  • End date
    Dec 15, 2021
  • participants needed
    75
  • sponsor
    Grupo Español de Investigación en Neurooncología
Updated on 15 February 2021
cancer
nitrosoureas
chemoradiotherapy
carmustine
temozolomide
brain tumor
therapeutic agent
alkylating agents
primary brain tumors

Summary

Glioblastomas (GBMs) are the most common malignant primary brain tumors. Despite multimodality aggressive therapies (surgery followed by chemoradiotherapy based on TMZ and adjuvant TMZ), median overall survival is only 12 to 15 months. This dramatic behavior is mainly due to the high invasiveness and proliferation rate of GBM.

In addition, GBM exhibits a high resistance to standard chemotherapy and radiotherapy. Current strategies for the treatment of GBM are only palliative, and include surgical resection (which is frequently incomplete due to the proximity of the tumour to vital brain structures) and focal radiotherapy. A large number of chemotherapeutic agents (e.g. alkylating agents such as TMZ and nitrosoureas such as carmustine) have also been tested, but they display limited efficacy.

The current gold standard first line treatment for glioma for patients less than 70 years old includes radiation and concurrent TMZ followed by adjuvant TMZ (i.e., the "Stupp regimen"). However, results are disappointing and there is an unmet medical need of new drugs in this setting.

Glasdegib (SHH pathway inhibitor) is a rational therapeutic agent for patients with newly diagnosed Glioblastoma since inhibits SHH pathway interfering with cancer stem cells and endothelial migration.

Details
Condition Glioblastoma Multiforme, glioblastoma
Treatment PF-04449913, Temozolomide Oral Capsule
Clinical Study IdentifierNCT03466450
SponsorGrupo Español de Investigación en Neurooncología
Last Modified on15 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 65 yrs?
Gender: Male or Female
Do you have Glioblastoma Multiforme?
Do you have any of these conditions: glioblastoma or Glioblastoma Multiforme?
Do you have any of these conditions: Glioblastoma Multiforme or glioblastoma?
Do you have any of these conditions: Glioblastoma Multiforme or glioblastoma?
Do you have any of these conditions: Glioblastoma Multiforme or glioblastoma?
Do you have any of these conditions: glioblastoma or Glioblastoma Multiforme?
Do you have any of these conditions: glioblastoma or Glioblastoma Multiforme?
Ability to understand and the willingness to sign a written informed consent document
Male or Female 18 years old
Newly diagnosed GBM confirmed by biopsy or resection no more than 4 to 6 weeks before registration
Patients candidates for Stupp treatment
Patients must have at least 15 unstained slides or 1 tissue block (frozen or paraffin embedded) available from a prior biopsy or surgery (archival tumor material)
Patients must have sufficient time for recovery from prior surgery (at least 4 weeks)
ECOG 1
Adequate hematologic function: Hematocrit 29%, Leukocytes > 3,000/mcL, ANC 1,500 cells/ul, platelets 100,000 cells/ul
Adequate liver function: Bilirubin 2 x ULN; AST (SGOT) 2.5 X ULN
Creatinine within normal institutional limits or creatinine clearance > 60 mL/min for subjects with creatinine levels above institutional normal
The effects of SHH pathway inhibitors on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence; surgical sterilization) prior to study entry and for the duration of study participation and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate
Should a woman become pregnant or suspect she is pregnant while participating
in this study, she should inform her treating physician immediately. All
female patients with reproductive potential must have a negative pregnancy
test (serum/urine) within 2 weeks prior to starting treatment
Female subjects must either be of non-reproductive potential (ie, post-menopausal by history: 60 years old and no menses for 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry

Exclusion Criteria

Presence of extracranial metastatic disease
Participants may not be receiving any other investigational agents
Patients must not have received prior Gliadel wafers
Any surgery (not including minor diagnostic procedures such as lymph node biopsy) within 2 weeks of baseline disease assessments; or not fully recovered from any side effects of previous procedures
Any psychiatric or cognitive disorder that would limit the understanding or rendering of informed consent and/or compromise compliance with the requirements of this protocol
Any clinically significant gastrointestinal abnormalities, which may impair intake, transit or absorption of the study drug, such as the inability to take oral medication in tablet form
Congenital or known history of long QT syndrome, Torsades de pointes, arrhythmias (including sustained ventricular tachyarrhythmia, right or left bundle branch block and bifascicular block, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (CHF New York Association class III or IV)
Current (or within 6 months) significant cardiovascular disease, including, but not limited to myocardial infarction, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism, bradycardia defined as <50 bpms
Active cardiac dysrhythmias of NCI CTCAE Grade 2 (eg, atrial fibrillation) or QTcF interval (QTc using Fridericia's formula) >470 msec
Active and clinically significant infections
Current use or anticipated requirement for drugs known to be moderate or strong cytochrome p450 inhibitors
Individuals with a history of a different malignancy are ineligible except for the following circumstances: Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin
Patients will not be eligible if they have evidence of other malignancy
requiring therapy other than surgery within the last 3 years
Patients who have had prior stereotactic radiotherapy, convection enhanced delivery or brachytherapy (as gliosis/scarring from these modalities may limit delivery)
Patients will not be eligible if they present with leptomeningeal dissemination
Pregnant women are excluded from this study because the potential for teratogenic or abortifacient effects is unknown (glasdegib has been shown to be teratogenic in nonclinical embryo-fetal development studies in rats and mice at subtherapeutic exposures). Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued if the mother is treated
HIV-positive individuals on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions. In addition, these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy
History of allergic reactions attributed to compounds of similar chemical or biologic composition to glasdegib
Other severe acute or chronic medical condition, uncontrolled intercurrent illness or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the patient inappropriate for entry into this trial
Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ highly effective birth control from screening to 180 days after the last dose of the study treatment
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note